

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO Box 1430 Alexandria, Virginia 22313-1450 www.tepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/593,911	05/11/2007	Steven A. Boyd	AV 35	6038
Henry D. Cole	7590 08/05/201 man	EXAMINER		
COLEMAN S	UDOL SAPONE, P.C.	MCDOWELL, BRIAN E		
714 Colorado Avenue Bridgeport, CT 06605-1601			ART UNIT	PAPER NUMBER
8-1,			1624	
			MAIL DATE	DELIVERY MODE
			08/05/2010	DADED

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

# Office Action Summary

Application No.	Applicant(s)					
10/593,911	BOYD ET AL.					
Examiner	Art Unit					
BRIAN MCDOWELL	1624					

	_						
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MALIND OATE OF THIS COMMUNICATION.  - Extensions or time may be available under the provisions of 37 CF1 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTH'S from the mailing date of the communication.							
<ul> <li>If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MCNITHS from the mating date of this communication.</li> <li>Failure to reply within the set or entended period for reply will, by statute, cause the application to become ARADONED (33 U.S.C. § 133).</li> <li>Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patter time adjustments. See 37 CFR 17 (MQb).</li> </ul>							
Status							
1) Responsive to communication(s) filed on 27 May 2010.							
2a)☑ This action is FINAL. 2b)☐ This action is non-final.							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) Claim(s) 1.2.4-11 and 23-25 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1.2.4-11.23-25</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
dec the attached detailed office action for a list of the continue copies not received.							
Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)							
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date							
3)   Information Disclosure Statement(s) (FTO/SB/08)   5)   Notice of Informat Patient Application   Paper No(s)/Mail Date   6)   Other:	-						

U.S. P	atent and	i Trade	nark	Offic
PTO	L-326	(Rev.	08-	06)

Art Unit: 1624

#### DETAILED ACTION

#### Status of Claims

Claims 1, 2, 4-11, and 23-25 are pending in the instant application.

### Previous Objections/Rejections

Any rejections or objections stated of record in the office action mailed on 3/4/2010 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 5/27/2010.

#### New Objections and Rejections

### Claim Objections

Claim 10 is objected to for the following:

A space should between the word "claim" and the number "1" in the preamble "The compound of claim1". Correction is required.

## Claim Rejections - 35 USC § 112 (2nd Paragraph)

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 8 and 9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1624

Claims 8 and 9 recite that variables "R<sup>7</sup> or R<sup>9</sup>" and "R<sup>7</sup>" may be selected from polysaccarides and/or amino acids shown in the latter part of claim 9, respectively. There is insufficient antecedent basis for these limitations in the daim since claim 1 does not embrace the aforementioned moieties for these particular variables.

## Claim Rejections - 35 USC § 112 (1st Paragraph)

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 2, 4-11, and 23-25 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for pharmaceutically acceptable salts, esters, salt of esters, stereoisomers, enantiomers, or tautomers of the claimed compounds, does not reasonably provide enablement for <u>isotopes</u> of the claimed compounds. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

Pursuant to *In re Wands*, 858 F.2d 731,737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988), one considers the following factors to determine whether undue experimentation is required:

- (A) The breadth of the claims;
- (B) The nature of the invention;
- (C) The state of the prior art;
- (D) The level of one of ordinary skill;
- (E) The level of predictability in the art;
- (F) The amount of direction provided by the inventor;

Page 4

Application/Control Number: 10/593,911

(G) The existence of working examples; and

Art Unit: 1624

(H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.

Some experimentation is not fatal; the issue is whether the amount of experimentation is "undue"; see *In re Vaeck*, 20 USPQ2d 1438, 1444. Analysis is described below:

- (A) Breadth of claims: The formula I is drawn to a myriad of isotopic derivatives of compounds of the formula I. The claims cover compounds (and their respective isotopically labeled analogues) easily in the millions given the number of possible rings, ring systems covered by the claims' scope along with varying choices for remaining variables: thus the claims are very broad.
- (B) The nature of the invention: The invention is closely related to the field of medicinal chemistry. More specifically, the issue at hand involves the direct incorporation of a myriad of unidentified isotopes into compounds of the formula I to treat cancer and other associated diseases.
- (C), (E), (F) State of the Prior Art: Chemistry is unpredictable. See *In Re Marzocchi* and Horton 169 USPQ at 367 paragraph 3:

"Most non-chemists would probably be horrified if they were to learn how many attempted syntheses fail, and how inefficient research chemists are. The ratio of successful to unsuccessful chemical experiments in a normal research laboratory is far below unity, and synthetic research chemists, in the same way as most scientists, spend most of their time working out what went wrong, and why. Despite the many pitfalls lurking in organic synthesis, most organic chemistry textbooks and research articles do give the impression that organic reactions just proceed smoothly and that the total synthesis of complex natural products, for instance, is maybe a labor-intensive but otherwise undemanding task.

Application/Control Number: 10/593,911

Art Unit: 1624

In fact, most syntheses of structurally complex natural products are the result of several years of hard work by a team of chemists, with almost every step requiring careful optimization. The final synthesis usually looks quite different from that originally planned, because of unexpected difficulties encountered in the initially chosen synthetic sequence. Only the seasoned practitioner who has experienced for himself the many failures and frustrations which the development (sometimes even the repetition) of a synthesis usually implies will be able to appraise such work ......Chemists tend not to publish negative results, because these are, as opposed to positive results, never definite (and far too copious)\* Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim pg. IX of Preface.

Applicant has provided adequate direction and guidance for preparing the instantly claimed compounds of formula I (see page 22 and below):

However, there is no guidance as to how to prepare and subsequently use isotopically labeled analogues of the final products. Furthermore to complicate the issue, applicant states that the claimed isotopes of formula I exclude those where hydrogen atoms are replaced by deuterium or tritium or carbon atoms which are replaced by <sup>13</sup>C or <sup>14</sup>C (see page 11 of specification). However, the majority of the

Art Unit: 1624

claimed compounds consist of hydrogen and carbon atoms! The disclosure lacks sufficient direction to guide the skilled artisan to readily incorporate unstable isotopically atoms such as sulfur, nitrogen, etc. into the claimed compounds of formula I. The disclosure also fails to identify the specific isotopes that are intended to be inserted into the claimed compounds (essential subject matter lacking). The specification simply states what is not to be included (e.g., deuterium, <sup>13</sup>C, <sup>14</sup>C, etc.), but fails to state which isotopes are intended to be included. If the identities of said isotopes are unknown, how can the skilled artisan possibly make and use the claimed invention? In addition, the examiner did not encounter a single compound in similar structure to those instantly claimed that possessed isotopically labeled atoms; further supporting that the art is highly unpredictable. The prior art search failed to reveal any compound with close chemical structure (yet alone isotopes thereof) to those claimed or procedures for incorporating isotopes into the structure of this class of compounds. Thus, it is imperative that the disclosure provides adequate guidance to the skilled artisan as to how (1) to make the claimed isotopes, (2) specifiv which isotopes are intended to be incorporated into the claim compounds and which ones are operative, and (3) how to subsequently use the claimed isotopically compounds of formula I.

- (D) Skill of those in the art: The level of skill in the art is high and one would require a Ph.D. in the field of synthetic organic chemistry.
- (G) Working Examples: The compound core depicted with specific substituents represent a narrow subgenus for which applicant has provided sufficient guidance to

Application/Control Number: 10/593,911

Art Unit: 1624

make and use; however, this disclosure is not sufficient to allow extrapolation of the limited examples to enable the scope of the compounds instantly claimed.

Within the specification, "specific operative embodiments or examples of the invention must be set forth. Examples and description should be of sufficient scope as to justify the scope of the claims. *Markush* claims must be provided with support in the disclosure for each member of the *Markush* group. Where the constitution and formula of a chemical compound is stated only as a probability or speculation, the disclosure is not sufficient to support claims identifying the compound by such composition or formula." See MPEP 608.01(p).

(H) The quantity of experimentation needed: Since there are very limited working examples as described above, the amount of experimentation is expected to be high and burdensome.

Due to the level of unpredictability in the art, the very limited guidance provided, and the lack of working examples, the applicant has shown lack of enablement. MPEP 2164.01(a) states, "A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. *In re Wright*, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)." That conclusion is clearly justified here.

Art Unit: 1624

#### Conclusion

No claims are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on Monday-Thursday 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1624

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/BRIAN MCDOWELL/ Patent Examiner, Art Unit 1624 /James O. Wilson/ Supervisory Patent Examiner, AU 1624